FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308376711> ?p ?o ?g. }

• W4308376711 abstract "<h3>Background</h3> T cell receptor (TCR)-based cell therapy to treat solid tumors by targeting tumor neoantigens is gaining momentum. While there is an urgent need for discovering novel TCRs, one challenge is that the exogenous TCR may compete with the endogenous TCR for CD3 signaling components and form mixed dimers with potential toxicities. Additionally, the activity of T cells highly depends on signaling machinery only present in T cells, which restricts the scope of eligible therapeutic cells. We developed a TCR-like chimeric-antigen-receptor to both overcome the mispairing of TCR α/β chains and to expand the scope of TCR-based cell therapy to other immune cells. <h3>Methods</h3> To identify novel TCRs, a monoclonal TCR discovery platform was developed. A high avidity TCR of a neoepitope-specific CD8+ T cell clone (CTL) that was generated from donor PBMCs was isolated and sequenced. A chimeric-antigen-receptor comprising an antigen binding domain (which is a portion of the identified TCR), a CD28 segment containing the hinge/transmembrane domain, and a cytoplasmic signaling domain containing a Dap10 and a Dap12 intracellular domains. To augment the avidity of the antigen receptor, a chimeric co-receptor was constructed by combining HLA-I binding domains of CD8α with the hinge/transmembrane/cytoplastic domains of CD4. T cell line (J.RT3-T3.5) and NK cell line (KYGH-1) were transduced by a lentivirus encoding the chimeric-antigen-receptor and co-receptor to assess their expression and function. <h3>Results</h3> Two novel TCRs specific for CTNNB1^S37F peptide (YLDSGIHFGA) and for p53^R175H peptide (HMTEVVRHC) respectively were identified; both are high-avidity and can recognize the endogenous neoepitope presented by HLA-A2 in tumor cells (figure 1A and B). A chimeric-antigen-receptor specific for CTNNB1^S37F neoepitope/HLA-A2 was expressed on the surface of 293T cells independent of endogenous CD3 (figure 2A). However, its avidity to recognize CTNNB1^S37F neoepitope was approximately 5 folds lower than that of the native TCR (figure 3A). Co-expression of the co-receptor could significantly enhance the avidity of the chimeric-antigen-receptor and make it capable of recognizing endogenously presented neoepitope in tumor cells (figure 3B). In addition, NK cells re-directed with the chimeric-antigen-receptor could also recognize the neoepitope peptide in the context of HLA-A2 (figure 2B and 4). <h3>Conclusions</h3> We validated a TCR-like chimeric-antigen-receptor that can be expressed on cells independent of endogenous CD3 and can recognize neoepitope/HLA-A2. We also designed and tested a co-receptor that can enhance the avidity of the chimeric-antigen-receptor. To further leverage the avidity of the chimeric-antigen-receptor, testing of new configurations of the chimeric-antigen-receptor and co-receptor is underway." @default.
• W4308376711 created "2022-11-11" @default.
• W4308376711 creator A5007816495 @default.
• W4308376711 creator A5048874956 @default.
• W4308376711 date "2022-11-01" @default.
• W4308376711 modified "2023-10-16" @default.
• W4308376711 title "230 TCR-like chimeric-antigen-receptor to recognize neoepitopes derived from driver mutations" @default.
• W4308376711 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0230" @default.
• W4308376711 hasPublicationYear "2022" @default.
• W4308376711 type Work @default.
• W4308376711 citedByCount "0" @default.
• W4308376711 crossrefType "proceedings-article" @default.
• W4308376711 hasAuthorship W4308376711A5007816495 @default.
• W4308376711 hasAuthorship W4308376711A5048874956 @default.
• W4308376711 hasBestOaLocation W43083767111 @default.
• W4308376711 hasConcept C147483822 @default.
• W4308376711 hasConcept C153911025 @default.
• W4308376711 hasConcept C154317977 @default.
• W4308376711 hasConcept C167672396 @default.
• W4308376711 hasConcept C179223381 @default.
• W4308376711 hasConcept C19317047 @default.
• W4308376711 hasConcept C202751555 @default.
• W4308376711 hasConcept C203014093 @default.
• W4308376711 hasConcept C2776090121 @default.
• W4308376711 hasConcept C3875195 @default.
• W4308376711 hasConcept C55493867 @default.
• W4308376711 hasConcept C86803240 @default.
• W4308376711 hasConcept C8891405 @default.
• W4308376711 hasConcept C95444343 @default.
• W4308376711 hasConceptScore W4308376711C147483822 @default.
• W4308376711 hasConceptScore W4308376711C153911025 @default.
• W4308376711 hasConceptScore W4308376711C154317977 @default.
• W4308376711 hasConceptScore W4308376711C167672396 @default.
• W4308376711 hasConceptScore W4308376711C179223381 @default.
• W4308376711 hasConceptScore W4308376711C19317047 @default.
• W4308376711 hasConceptScore W4308376711C202751555 @default.
• W4308376711 hasConceptScore W4308376711C203014093 @default.
• W4308376711 hasConceptScore W4308376711C2776090121 @default.
• W4308376711 hasConceptScore W4308376711C3875195 @default.
• W4308376711 hasConceptScore W4308376711C55493867 @default.
• W4308376711 hasConceptScore W4308376711C86803240 @default.
• W4308376711 hasConceptScore W4308376711C8891405 @default.
• W4308376711 hasConceptScore W4308376711C95444343 @default.
• W4308376711 hasLocation W43083767111 @default.
• W4308376711 hasOpenAccess W4308376711 @default.
• W4308376711 hasPrimaryLocation W43083767111 @default.
• W4308376711 hasRelatedWork W1517459791 @default.
• W4308376711 hasRelatedWork W1558649589 @default.
• W4308376711 hasRelatedWork W2033962007 @default.
• W4308376711 hasRelatedWork W2044087908 @default.
• W4308376711 hasRelatedWork W2063492259 @default.
• W4308376711 hasRelatedWork W2073820757 @default.
• W4308376711 hasRelatedWork W2121315503 @default.
• W4308376711 hasRelatedWork W2125066454 @default.
• W4308376711 hasRelatedWork W2140341414 @default.
• W4308376711 hasRelatedWork W2140574666 @default.
• W4308376711 isParatext "false" @default.
• W4308376711 isRetracted "false" @default.
• W4308376711 workType "article" @default.